Merz Therapeutics and Acino signed a distribution agreement
- Acino will commercialize Merz Therapeutics’ present portfolio of products in the fields of gastroenterology, neurology and dermatology including hair loss in Ukraine, Belarus, Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan and Mongolia.
Pharmaceutical Group of Companies Acino (Switzerland) has signed the exclusive distribution agreement with Merz Therapeutics (Germany), a business of Merz Pharmaceuticals GmbH, for commercial sales and promotion of a number of Merz Therapeutics products in Ukraine, CIS region and Mongolia, excluding Russia, effective July 1st, 2021.
Under the terms of this agreement, Acino will commercialize the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology (hepatic encephalopathy, Parkinson’s disease, scar and hair treatment) in Ukraine, Belarus, Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan and Mongolia.
The following trademarks are covered by the agreement: HEPA-MERZ®, PK-MERZ®, PANTOGAR®, CONTRACTUBEX®, in ten SKUs.
“Partnership is the integral part of our strategy. This agreement further strengthens our presence in CIS region and neighboring countries where we have established ourselves as a reliable manufacturer and leading provider of high-quality pharmaceuticals. With these brands, we enhanced the offer of our portfolio, providing the access for patients and healthcare professionals to innovative medicine products in selected markets. As a trusted partner we will perform import, distribution, marketing as well as patients’ awareness-raising of diseases covered by this agreement”, noticed Eugene Zaika, Regional Head Ukraine and CIS of Acino.
Acino establishes a strong market footprint in Ukraine and CIS region and neighboring countries creating new jobs locally, in order to ensure continuous access of high-quality medicines in emerging markets. Acino’s market share in Ukraine, reaching over 3,3% , and making the Top-5 list of pharmaceutical companies. Here the company ranks the leading positions in psychiatry, neurology, cardiology and endocrinology therapeutic areas.
“Partnership is a central strategic element at Merz Therapeutics. Therefore, I am very pleased to announce the distribution agreement we have just signed with ACINO. I am glad that we have found a partner to whom partnership is as important as it is to us. I am looking forward to a collaborative partnership that is valued on both sides and is built on trust and aims to bring excellent performance to the market. Of course, this is another step, that supports our company in our mission to bring better outcomes to more patients”, Andrea von der Lippe, VP, Head of Global Distribution Partner Management at Merz Therapeutics.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs. For more information, please visit: www.merz.com/our-businesses/therapeutics/.
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the CIS Region, Middle East, Russia, Africa and Latin America. The company is backed by Nordic Capital and Avista Capital Partners. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets, and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information, visit www.acino.swiss.
* * *
 Drugs and dietary supplements H1 2021 according to the PharmXplrorer Retail analytics data by Proxima Research company.